During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall ...

James O’Mara is president and chief executive officer at, Neurogastrx, Inc.

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, ...

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of ...